Business
Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates
Lantern is expanding RADR®’s product roadmap to enhance the development of novel and effective Antibody Drug Conjugates (ADCs) for the targeted delivery of
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nLantern is expanding RADR®’s product roadmap to enhance the development of novel and effective Antibody Drug Conjugates (ADCs) for the targeted delivery of potent anti-cancer small molecules to cancer cells.\n\n\nRADR®’s AI and ML drug development modules have the potential to assist in advancing ADC drug candidates from the discovery phase to first-in-human clinical trials in approximately 2 years or less.\n\n\nLantern anticipates this expansion will significantly add to RADR®’s 25+ billion oncology focused data points and library of over 200+ algorithms.\n\n\nThe global ADC market is over $4.0 billion and is projected to reach $14.0 billion by 2027.\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"AI\") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced expansions and updates to RADR®’s product roadmap, which will further enhance its oncology drug discovery capabilities. These RADR® advancements will focus on additional innovative AI and ML approaches to develop Antibody Drug Conjugates (ADCs), which are highly specific cancer-targeted antibodies linked to potent anti-tumor small molecules and designed for the treatment of cancer.\n\n“RADR® is an integral component for de-risking and powering the progression of Lantern’s drug programs, and our recent advances in moving from program identification through preclinical development have occurred at speeds rarely seen in oncology drug discovery and development,” said Panna Sharma, Lantern’s CEO and President. “Globally, ADC drug programs are one of the fastest growing drug development markets and are projected to represent a global market potential of over $14 billion by 2027. The expansion of RADR®’s ADC capabilities will not only build on its demonstrated ability to identify synergistic and effective combinations of antibodies and small molecules, but will also facilitate new high-value ADC-focused business development opportunities and collaborations,” continued Sharma.\n\nHighlights of RADR®’s ADC Development Roadmap:\n\nLantern’s strategic RADR® roadmap for the development of ADCs was implemented this quarter and will include the following expansions and updates:\n\n\nDe...